David Lee began his path to CEO of Lumicell in 1999, when his wife was diagnosed with cancer. She passed away in 2003, while Lee was working in the semiconductor industry. He decided it was time for a career change.
More than a decade later, Lee holds the corner office at a company that is developing a hand-held imaging system to detect residual cancer and treat it in real-time. The product is in Phase IIb testing and in 45 patients, the device has not yet missed any cancer.
“We have a 100% batting average,” Lee told a crowd last week at MassBio’s event, The Convergence of Medical Devices & Drugs: The Future of Combination Products.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!